, Lancet Lond Engl. 18 juin, vol.377, issue.9783, pp.2127-2164, 2011.
The natural disease course of ankylosing spondylitis, Arthritis Rheum. févr, vol.26, issue.2, pp.186-90, 1983. ,
Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?, Ann Rheum Dis. juill, vol.64, issue.7, pp.988-94, 2005. ,
The effects of structural damage on functional disability in psoriatic arthritis, Ann Rheum Dis. déc, vol.76, issue.12, pp.2038-2083, 2017. ,
Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis, Best Pract Res Clin Rheumatol. juin, vol.32, issue.3, pp.369-89, 2018. ,
The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis, Curr Opin Rheumatol. juill, vol.26, issue.4, pp.361-70, 2014. ,
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants, Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), vol.39, pp.1329-1366, 2007. ,
HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats, Arthritis Rheum. sept, vol.60, issue.9, pp.2633-2676, 2009. ,
Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats, Arthritis Rheum. janv, vol.64, issue.1, pp.110-130, 2012. ,
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides, Arthritis Rheum. août, vol.58, issue.8, pp.2307-2324, 2008. ,
Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response, Arthritis Res Ther. 20 juin, vol.13, issue.3, p.95, 2011. ,
IL-23 induces spondyloarthropathy by acting on ROR-?t+ CD3+CD4-CD8-entheseal resident T cells, Nat Med. 1 juill, vol.18, issue.7, pp.1069-76, 2012. ,
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial, Lancet Lond Engl. 31 août, vol.382, issue.9894, pp.780-789, 2013. ,
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial, Ann Rheum Dis. juin, vol.73, issue.6, pp.990-999, 2014. ,
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials, Ann Rheum Dis. juin, vol.73, issue.6, pp.1000-1006, 2014. ,
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial, Arthritis Care Res. déc, vol.67, issue.12, pp.1739-1788, 2015. ,
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis, N Engl J Med, vol.373, issue.14, pp.1329-1368, 2015. ,
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Lond Engl, vol.386, issue.9999, pp.1137-1183, 2015. ,
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis, N Engl J Med. 24 déc, vol.373, issue.26, pp.2534-2582, 2015. ,
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3, Arthritis Res Ther, vol.22, issue.1, p.285, 2017. ,
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE), Clin Rheumatol. mars, vol.37, issue.3, pp.667-75, 2018. ,
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study, Clin Rheumatol. févr, vol.37, issue.2, pp.397-405, 2018. ,
Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study, Clin Rheumatol. juill, vol.36, issue.7, pp.1589-93, 2017. ,
Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab, J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. oct, vol.24, issue.7, pp.381-385, 2018. ,
,
, Therapie. juin, vol.71, issue.3, pp.281-287, 2016.
Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice, Clin Rheumatol. févr, vol.36, issue.2, pp.439-482, 2017. ,
American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis, Arthritis Care Res. janv, vol.71, issue.1, pp.2-29, 2018. ,
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis. mars, vol.75, issue.3, pp.499-510, 2016. ,
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis: GRAPPA TREATMENT RECOMMENDATIONS FOR PsA, Arthritis Rheumatol. mars, 2016. ,
Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis, Arthritis Care Res, 2019. ,
,
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis, Ann Rheum Dis. juin, vol.76, issue.6, pp.978-91, 2017. ,
2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis, Joint Bone Spine. mai, vol.85, issue.3, pp.275-84, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01794588
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
, , vol.17
,
,
,
,
,
) Rheumatology, Henri Mondor Hospital, Rheumatology, Bichat Hospital, issue.5 ,
, Rheumatology, issue.10
14) Rheumatology, Hospital of Valenciennes, Valenciennes, Private Practice, vol.54, issue.12, pp.623-631, 2018. ,
,
,
,
,
,
,
,
,
,
,
,
,
,
, , vol.12
,
,
,
,
,
, , vol.17
,
, , vol.20
, , vol.20
,
,
,
, , vol.13, p.0
) Rheumatology, Henri Mondor Hospital, Rheumatology, Bichat Hospital, issue.6 ,
,
, Among the axSpA cohort, evidence of radiographic sacroiliitis, MRI sacroiliitis or elevated CRP were also assessed as potential predictors. Drug survival was analyzed by the Kaplan-Meier method and adjusted for baseline factors were estimated by multiple Cox regression analysis. Results : The main characteristics of the 556 patients (pts) included were the following: 338 (61%) axSpA , 183 (33%) PsA, 324 (58%) female, mean age 47 +/-12 years, 221 (40%) smokers,160 (29%) radiographic sacroiliitis, 238 (43%) MRI sacroiliitis, 206 (37%) elevated CRP, 239 (43%) HLA B27 positive, mean BASDAI 48,9 +/-27%. SEC was associated to methotrexate (MTX) in 140 pts (25%) and was the first line bDMARD in 56 patients (10%). The median drug survival (MDS) of SEC was 76 weeks (w), Private Practice, vol.54, issue.13, pp.65-88, 2016.